GlassScriptPhysician profile
Kate L Leon
NPI 1467970228
$3,978.52
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $531 · 2023: $1,490 · 2024: $1,957.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,433 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,433.28 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $737.14 | 2023-2024 | |
| Novo Nordisk INC | $686.76 | 2022-2024 | Rybelsus, Ozempic, Wegovy |
| Biotissue Holdings INC. | $501.47 | 2024 | |
| Pfizer INC. | $420.68 | 2023-2024 | |
| Lilly USA, LLC | $411.56 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $121.34 | 2022-2024 | |
| Abbott Laboratories | $119.50 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Dexcom, INC. | $118.18 | 2022-2024 | Dexcom G6 Transmitter |
| Amgen INC. | $100.84 | 2022-2024 | Repatha, Otezla |
| Biohaven Pharmaceutical Holding Company LTD. | $80.08 | 2022 | |
| Shield Therapeutics INC | $77.01 | 2023-2024 | Accrufer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.58 | 2022-2024 | Jardiance |
| Glaxosmithkline, LLC. | $71.25 | 2023-2024 | Trelegy Ellipta |
| Idorsia Pharmaceuticals US INC | $70.05 | 2023-2024 | Quviviq |
| Currax Pharmaceuticals LLC | $69.30 | 2022-2024 | Contrave |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.18 | 2023-2024 | Xifaxan, Ibschek |
| Sumitomo Pharma America, INC. | $45.00 | 2024 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $41.84 | 2023-2024 | |
| Lucid Diagnostics INC. | $30.75 | 2023 | |
| Exact Sciences Corporation | $29.42 | 2024 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $26.93 | 2024 | Injectafer |
| Astrazeneca Pharmaceuticals LP | $23.40 | 2024 | Airsupra |
| Cranial Technologies, INC | $19.68 | 2022 | |
| Hologic Sales and Service, LLC | $18.15 | 2022 | |
| Mannkind Corporation | $17.59 | 2022 | |
| Nevro Corp. | $14.84 | 2023 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kate Leon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.